# A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema

> **NCT07290855** · PHASE4 · COMPLETED · sponsor: **Nang Kuang Pharmaceutical Co., Ltd.** · enrollment: 5 (actual)

## Conditions studied

- Bradykinin-mediated Angioedema
- Hereditary Angioedema (HAE)

## Interventions

- **DRUG:** Icatibant Injection (Icanticure®)

## Key facts

- **NCT ID:** NCT07290855
- **Lead sponsor:** Nang Kuang Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-27
- **Primary completion:** 2025-05-27
- **Final completion:** 2025-09-26
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07290855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07290855, "A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07290855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*